in Cardiac Valves
The first artificial heart valve
designed to be both:
free of anticoagulation therapy
- durable for life
Novostia SA is dedicated to advancing this innovative medical device to clinical trials and regulatory approvals.
Finally, an answer to a large and growing unmet need worldwide—especially among young patients in developed and emerging economies.
Preclinical evidence supporting product safety and effectiveness.
Support from internationally renowned cardiac surgeons and fluid dynamics experts.
I have been impressed by the Lapeyre-Triflo valve and
look forward to starting first-in-man clinical trials.
This valve has the potential to benefit thousands of patients, especially young people.
Prof. Thierry Carrel, M.D.
University Hospital of Bern, Switzerland
A new generation of artificial valves
combining the best of existing worlds
New high-performance biocompatible material.
A unique anatomic tri-leaflet design with a physiological operating mode.
Like native valves, the Lapeyre-Triflo valve closes early and gently during flow deceleration
—and not by the reverse flow as in current mechanical heart valves—
thus not generating a haemostatic response.